KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$167.9 million.

  • Vir Biotechnology's Free Cash Flow rose 365.05% to -$167.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$460.0 million, marking a year-over-year increase of 284.4%. This contributed to the annual value of -$453.7 million for FY2024, which is 4331.87% up from last year.
  • Vir Biotechnology's Free Cash Flow amounted to -$167.9 million in Q3 2025, which was up 365.05% from -$122.8 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Free Cash Flow high stood at $939.5 million for Q2 2022, and its period low was -$398.7 million during Q2 2023.
  • In the last 5 years, Vir Biotechnology's Free Cash Flow had a median value of -$90.2 million in 2021 and averaged -$5.2 million.
  • As far as peak fluctuations go, Vir Biotechnology's Free Cash Flow skyrocketed by 125156.9% in 2021, and later plummeted by 58537.6% in 2023.
  • Over the past 5 years, Vir Biotechnology's Free Cash Flow (Quarter) stood at -$5.4 million in 2021, then skyrocketed by 519.81% to $22.6 million in 2022, then crashed by 585.38% to -$109.5 million in 2023, then grew by 18.12% to -$89.6 million in 2024, then crashed by 87.31% to -$167.9 million in 2025.
  • Its last three reported values are -$167.9 million in Q3 2025, -$122.8 million for Q2 2025, and -$79.7 million during Q1 2025.